Download PDF
Semin Thromb Hemost 2000; Volume 26(Number 03): 281-290
DOI: 10.1055/s-2000-8472
Copyright © 2000 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Hyperhomocysteinemia, Vascular Pathology, and Endothelial Dysfunction

COEN. VAN GULDENER, COEN. D.A. STEHOUWER
  • Department of Internal Medicine, University Hospital and Institute for Cardiovascular Research Vrije Universiteit, Amsterdam, The Netherlands
Further Information

Publication History

Publication Date:
31 December 2000 (online)

    Permissions and Reprints

ABSTRACT

Hyperhomocysteinemia has been associated with premature atherothrombotic vascular disease. It is not known whether hyperhomocysteinemia induces a distinct type of vascular disease. Its interaction, if any, with traditional risk factors also remains unclear. The pathophysiological mechanisms linking hyperhomocysteinemia to vascular disease have been extensively studied in vitro and in animals. From these studies, it has been suggested that homocysteine limits the bioavailability of nitric oxide (NO), increases oxidative stress, stimulates smooth cell proliferation, and alters elastic wall properties. The relevance of these proposed mechanisms in vivo is unclear, because clinical studies have yielded controversial results with regard to the relation between plasma homocysteine levels and indices of endothelial function, such as brachial artery flow-mediated vasodilatation and plasma levels of endothelium-derived marker proteins. Up till now, there have been no controlled data on the effects of homocysteine-lowering treatment on vascular function or clinical end points. The precise mechanisms (if any) by which homocysteine mediates its adverse vascular effects are in fact unknown but may relate to impaired endothelial and smooth muscle cell function.

KEYWORD

Hyperhomocysteinemia - vascular dis- eases - endothelial function - treatment - athero-thrombosis

REFERENCES

  • 1 Perry I J, Refsum H, Morris R W. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men.  Lancet . 1995;  346 1395-1398
    CrossrefPubMedGoogle Scholar
  • 2 Taylor L MJ, DeFrang R D, Harris E JJ, Porter J M. The association of elevated plasma homocyst(e)ine with progression of symptomatic peripheral arterial disease.  J Vasc Surg . 1991;  13 128-136
    PubMedGoogle Scholar
  • 3 Wald N J, Watt H C, Law M R. Homocysteine and ischemic heart disease: Results of a prospective study with implications regarding prevention.  Arch Intern Med . 1998;  158 862-867
    CrossrefPubMedGoogle Scholar
  • 4 den Heijer M, Koster T, Blom H J. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis.  N Engl J Med . 1996;  334 759-762
    Google Scholar
  • 5 Graham I M, Daly L E, Refsum H M. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project.  JAMA . 1997;  277 1775-1781
    CrossrefPubMedGoogle Scholar
  • 6 Evans R W, Shaten B J, Hempel J D, Cutler J A, Kuller L H. Homocyst(e)ine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial.  Arterioscler Thromb Vasc Biol . 1997;  17 1947-1953
    PubMedGoogle Scholar
  • 7 Wang H, Yoshizumi M, Lai K. Inhibition of growth and p21ras methylation in vascular endothelial cells by homocysteine but not cysteine.  J Biol Chem . 1997;  272 25380-25385
    CrossrefPubMedGoogle Scholar
  • 8 Perna A F, Ingrosso D, Galletti P, Zappia V, De Santo N G. Membrane protein damage and methylation reactions in chronic renal failure.  Kidney Int . 1996;  50 358-366
    PubMedGoogle Scholar
  • 9 McCully K S. Vascular pathology of homocysteinemia: Implications for the pathogenesis of arteriosclerosis.  Am J Pathol . 1969;  56 111-128
    Google Scholar
  • 10 Gibson J B, Carson N AJ, Neill D W. Pathological findings in homocystinuria.  J Clin Pathol . 1964;  17 427-437
    PubMedGoogle Scholar
  • 11 Harker L A, Ross R, Slichter S J, Scott C R. Homocystine-induced arteriosclerosis.  The role of endothelial cell injury and platelet response in its genesis. J Clin Invest . 1976;  58 731-741
    PubMedGoogle Scholar
  • 12 McCully K S, Ragsdale B D. Production of arteriosclerosis by homocysteinemia.  Am J Pathol . 1970;  61 1-11
    PubMedGoogle Scholar
  • 13 Reddy G S, Wilcken D E. Experimental homocysteinemia in pigs: Comparison with studies in sixteen homocystinuric patients.  Metabolism . 1982;  31 778-783
    CrossrefPubMedGoogle Scholar
  • 14 Dudman N P, Wilcken D E. Homocysteine thiolactone and experimental homocysteinemia.  Biochem Med . 1982;  27 244-253
    CrossrefPubMedGoogle Scholar
  • 15 Matthias D, Becker C H, Riezler R, Kindling P H. Homocysteine induced arteriosclerosis-like alterations of the aorta in normotensive and hypertensive rats following application of high doses of methionine.  Atherosclerosis . 1996;  122 201-216
    CrossrefPubMedGoogle Scholar
  • 16 McCully K S, Wilson R B. Homocysteine theory of arteriosclerosis.  Atherosclerosis . 1975;  22 215-227
    PubMedGoogle Scholar
  • 17 Rolland P H, Friggi A, Barlatier A. Hyperhomocysteinemia-induced vascular damage in the minipig. Captopril-hydrochlorothiazide combination prevents elastic alterations.  Circulation . 1995;  91 1161-1174
    PubMedGoogle Scholar
  • 18 Ubbink J B, Vermaak W J, Bennett J M. The prevalence of homocysteinemia and hypercholesterolemia in angiographically defined coronary heart disease.  Klin Wochenschr . 1991;  69 527-534
    CrossrefPubMedGoogle Scholar
  • 19 von Eckardstein A, Malinow M R, Upson B. Effects of age, lipoproteins, and hemostatic parameters on the role of homocyst(e)inemia as a cardiovascular risk factor in men.  Arterioscler Thromb . 1994;  14 460-464
    PubMedGoogle Scholar
  • 20 Nygard O, Nordrehaug J E, Refsum H. Plasma homocysteine levels and mortality in patients with coronary artery disease.  N Engl J Med . 1997;  337 230-236
    CrossrefPubMedGoogle Scholar
  • 21 Verhoef P, Kok F J, Kruyssen D A. Plasma total homocysteine, B vitamins, and risk of coronary atherosclerosis.  Arterioscler Thromb Vasc Biol . 1997;  17 989-995
    PubMedGoogle Scholar
  • 22 Montalescot G, Ankri A, Chadefaux-Vekemans B. Plasma homocysteine and the extent of atherosclerosis in patients with coronary artery disease.  Int J Cardiol . 1997;  60 295-300
    CrossrefPubMedGoogle Scholar
  • 23 Yoo J H, Chung C S, Kang S S. Relation of plasma homocyst(e)ine to cerebral infarction and cerebral atherosclerosis.  Stroke . 1998;  29 2478-2483
    PubMedGoogle Scholar
  • 24 Fassbender K, Mielke O, Bertsch T. Homocysteine in cerebral macroangiopathy and microangiopathy.  Lancet . 1999;  353 1586-1587
    CrossrefPubMedGoogle Scholar
  • 25 van den Berg M, Stehouwer C D, Bierdrager E, Rauwerda J A. Plasma homocysteine and severity of atherosclerosis in young patients with lower-limb atherosclerotic disease.  Arterioscler Thromb Vasc Biol . 1996;  16 165-171
    PubMedGoogle Scholar
  • 26 Selhub J, Jacques P F, Bostom A G. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis.  N Engl J Med . 1995;  332 286-291
    CrossrefPubMedGoogle Scholar
  • 27 de Jong S C, Stehouwer C D, Mackaay A J. High prevalence of hyperhomocysteinemia and asymptomatic vascular disease in siblings of young patients with vascular disease and hyperhomocysteinemia.  Arterioscler Thromb Vasc Biol . 1997;  17 2655-2662
    PubMedGoogle Scholar
  • 28 Clarke R, Fitzgerald D, O'Brien C. Hyperhomocysteinaemia: A risk factor for extracranial carotid artery atherosclerosis.  Ir J Med Sci . 1992;  161 61-65
    PubMedGoogle Scholar
  • 29 Malinow M R, Nieto F J, Szklo M, Chambless L E, Bond G. Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults. The Atherosclerosis Risk in Communities Study.  Circulation . 1993;  87 1107-1113
    PubMedGoogle Scholar
  • 30 Demuth K, Moatti N, Hanon O. Opposite effects of plasma homocysteine and the methylenetetrahydrofolate reductase C677T mutation on carotid artery geometry in asymptomatic adults.  Arterioscler Thromb Vasc Biol . 1998;  18 1838-1843
    PubMedGoogle Scholar
  • 31 Rubba P, Mercuri M, Faccenda F. Premature carotid atherosclerosis: Does it occur in both familial hypercholesterolemia and homocystinuria?.  <~>Ultrasound assessment of arterial intima-media thickness and blood flow velocity. Stroke . 1994;  25 943-950
    PubMedGoogle Scholar
  • 32 de Valk H W, van Eeden M K, Banga J D. Evaluation of the presence of premature atherosclerosis in adults with heterozygosity for cystathionine-beta-synthase deficiency.  Stroke . 1996;  27 1134-1136
    PubMedGoogle Scholar
  • 33 Tonstad S, Joakimsen O, Stensland-Bugge E. Risk factors related to carotid intima-media thickness and plaque in children with familial hypercholesterolemia and control subjects.  Arterioscler Thromb Vasc Biol . 1996;  16 984-991
    PubMedGoogle Scholar
  • 34 Smilde T J, van den Berkmortel F WPJ, Boers G HJ. Carotid and femoral artery wall thickness and stiffness in patients at risk for cardiovascular disease, with special emphasis on hyperhomocysteinemia.  Arterioscler Thromb Vasc Biol . 1998;  18 1958-1963
    PubMedGoogle Scholar
  • 35 Megnien J L, Gariepy J, Saudubray J M. Evidence of carotid artery wall hypertrophy in homozygous homocystinuria.  Circulation . 1998;  98 2276-2281
    PubMedGoogle Scholar
  • 36 Bots M L, Launer L J, Lindemans J, Hofman A, Grobbee D E. Homocysteine, atherosclerosis and prevalent cardiovascular disease in the elderly: The Rotterdam Study.  J Intern Med . 1997;  242 339-347
    CrossrefPubMedGoogle Scholar
  • 37 McQuillan B M, Beilby J P, Nidorf M, Thompson P L, Hung J. Hyperhomocysteinemia but not the C677T mutation of methylenetetrahydrofolate reductase is an independent risk determinant of carotid wall thickening. The Perth Carotid Ultrasound Disease Assessment Study (CUDAS).  Circulation . 1999;  99 2383-2388
    PubMedGoogle Scholar
  • 38 Spence J D, Malinow M R, Barnett P A. Plasma homocyst(e)ine concentration, but not MTHFR genotype, is associated with variation in carotid plaque area.  Stroke . 1999;  30 969-973
    PubMedGoogle Scholar
  • 39 Jackson S H. The reaction of homocysteine with aldehyde: An explanation of the collagen defects in homocystinuria.  Clin Chim Acta . 1973;  45 215-217
    CrossrefPubMedGoogle Scholar
  • 40 Kang A H, Trelstad R L. A collagen defect in homocystinuria.  J Clin Invest . 1973;  52 2571-2578
    PubMedGoogle Scholar
  • 41 Tawakol A, Omland T, Gerhard M, Wu J T, Creager M A. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans.  Circulation . 1997;  95 1119-1121
    PubMedGoogle Scholar
  • 42 Woo K S, Chook P, Lolin Y I. Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans.  Circulation . 1997;  96 2542-2544
    PubMedGoogle Scholar
  • 43 Lambert J, van den Berg M, Steyn M. Familial hyperhomocysteinaemia and endothelium-dependent vasodilatation and arterial distensibility of large arteries.  Cardiovasc Res . 1999;  42 743-751
    CrossrefPubMedGoogle Scholar
  • 44 van Guldener C, Lambert J, Janssen M JFM, Donker A JM, Stehouwer C DA. Endothelium-dependent vasodilatation and distensibility of large arteries in chronic haemodialysis patients.  Nephrol Dial Transplant . 1997;  14-18 (14-18)
    PubMedGoogle Scholar
  • 45 Blacher J, Demuth K, Guerin A P. Influence of biochemical alterations on arterial stiffness in patients with end-stage renal disease.  Arterioscler Thromb Vasc Biol . 1998;  18 535-541
    PubMedGoogle Scholar
  • 46 Tsai J C, Perrella M A, Yoshizumi M. Promotion of vascular smooth muscle cell growth by homocysteine: A link to atherosclerosis.  Proc Natl Acad Sci USA . 1994;  91 6369-6373
    PubMedGoogle Scholar
  • 47 Lubec B, Labudova O, Hoeger H. Homocysteine increases cyclin- dependent kinase in aortic rat tissue.  Circulation . 1996;  94 2620-2625
    PubMedGoogle Scholar
  • 48 Majors A, Ehrhart L A, Pezacka E H. Homocysteine as a risk factor for vascular disease.  Enhanced collagen production and accumulation by smooth muscle cells. Arterioscler Thromb Vasc Biol . 1997;  17 2074-2081
    PubMedGoogle Scholar
  • 49 Jawien A, Bowen-Pope D F, Lindner V, Schwartz S M, Clowes A W. Platelet- derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty.  J Clin Invest . 1992;  89 507-511
    PubMedGoogle Scholar
  • 50 Jackson C L, Raines E W, Ross R, Reidy M A. Role of endogenous platelet- derived growth factor in arterial smooth muscle cell migration after balloon catheter injury.  Arterioscler Thromb . 1993;  13 1218-1226
    PubMedGoogle Scholar
  • 51 Ross R. The pathogenesis of atherosclerosis: A perspective for the 1990s.  Nature . 1993;  362 801-809
    CrossrefPubMedGoogle Scholar
  • 52 Wall R T, Harlan J M, Harker L A, Striker G E. Homocysteine-induced endothelial cell injury in vitro: A model for the study of vascular injury.  Thromb Res . 1980;  18 113-121
    CrossrefPubMedGoogle Scholar
  • 53 Dudman N P, Hicks C, Wang J, Wilcken D E. Human arterial endothelial cell detachment in vitro: Its promotion by homocysteine and cysteine.  Atherosclerosis . 1991;  91 77-83
    PubMedGoogle Scholar
  • 54 Starkebaum G, Harlan J M. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine.  J Clin Invest . 1986;  77 1370-1376
    CrossrefPubMedGoogle Scholar
  • 55 Blundell G, Jones B G, Rose F A, Tudball N. Homocysteine mediated endothelial cell toxicity and its amelioration.  Atherosclerosis . 1996;  122 163-172
    CrossrefPubMedGoogle Scholar
  • 56 Blann A D. Endothelial cell damage and homocysteine.  Atherosclerosis . 1992;  94 89-91
    PubMedGoogle Scholar
  • 57 Stamler J S, Osborne J A, Jaraki O. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen.  J Clin Invest . 1993;  91 308-318
    PubMedGoogle Scholar
  • 58 Jones B G, Rose F A, Tudball N. Lipid peroxidation and homocysteine induced toxicity.  Atherosclerosis . 1994;  105 165-170
    CrossrefPubMedGoogle Scholar
  • 59 Heinecke J W, Kawamura M, Suzuki L, Chait A. Oxidation of low density lipoprotein by thiols: Superoxide-dependent and -independent mechanisms.  J Lipid Res . 1993;  34 2051-2061
    PubMedGoogle Scholar
  • 60 Nishio E, Watanabe Y. Homocysteine as a modulator of platelet-derived growth factor action in vascular smooth muscle cells: A possible role for hydrogen peroxide.  Br J Pharmacol . 1997;  122 269-274
    CrossrefPubMedGoogle Scholar
  • 61 Upchurch G RJ, Welch G N, Fabian A J. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase.  J Biol Chem . 1997;  272 17012-17017
    CrossrefPubMedGoogle Scholar
  • 62 Upchurch G RJ, Welch G N, Fabian A J. Stimulation of endothelial nitric oxide production by homocyst(e)ine.  Atherosclerosis . 1997;  132 177-185
    CrossrefPubMedGoogle Scholar
  • 63 Celermajer D S, Sorensen K, Ryalls M. Impaired endothelial function occurs in the systemic arteries of children with homozygous homocystinuria but not in their heterozygous parents.  J Am Coll Cardiol . 1993;  22 854-858
    CrossrefPubMedGoogle Scholar
  • 64 Lentz S R, Sobey C G, Piegors D J. Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia.  J Clin Invest . 1996;  98 24-29
    PubMedGoogle Scholar
  • 65 Welch G N, Upchurch G RJ, Farivar R S. Homocysteine-induced nitric oxide production in vascular smooth-muscle cells by NF-kappa B-dependent transcriptional activation of Nos2.  Proc Assoc Am Phys . 1998;  110 22-31
    PubMedGoogle Scholar
  • 66 Ikeda U, Ikeda M, Minota S, Shimada K. Homocysteine increases nitric oxide synthesis in cytokine-stimulated vascular smooth muscle cells.  Circulation . 1999;  99 1230-1235
    PubMedGoogle Scholar
  • 67 Quere I, Hillaire-Buys D, Brunschwig C. Effects of homocysteine on acetylcholine- and adenosine-induced vasodilatation of pancreatic vascular bed in rats.  Br J Pharmacol . 1997;  122 351-357
    CrossrefPubMedGoogle Scholar
  • 68 Ungvari Z, Pacher P, Rischak K, Szollar L, Koller A. Dysfunction of nitric oxide mediation in isolated rat arterioles with methionine diet-induced hyperhomocysteinemia.  Arterioscler Thromb Vasc Biol . 1999;  19 1899-1904
    PubMedGoogle Scholar
  • 69 Joannides R, Haefeli W E, Linder L. Nitric oxide is responsible for flow- dependent dilatation of human peripheral conduit arteries in vivo.  Circulation . 1995;  91 1314-1319
    CrossrefPubMedGoogle Scholar
  • 70 Meredith I T, Currie K E, Anderson T J. Postischemic vasodilation in human forearm is dependent on endothelium-derived nitric oxide.  Am J Physiol . 1996;  270 H1435-H1440
    PubMedGoogle Scholar
  • 71 Anderson T J, Uehata A, Gerhard M D. Close relation of endothelial function in the human coronary and peripheral circulations.  J Am Coll Cardiol . 1995;  26 1235-1241
    CrossrefPubMedGoogle Scholar
  • 72 Neunteufl T, Katzenschlager R, Hassan A. Systemic endothelial dysfunction is related to the extent and severity of coronary artery disease.  Atherosclerosis . 1997;  129 111-118
    CrossrefPubMedGoogle Scholar
  • 73 van Guldener C, Janssen M JFM, Lambert J. Endothelium-dependent vasodilatation is impaired in peritoneal dialysis patients.  Nephrol Dial Transplant . 1998;  13 1782-1786
    PubMedGoogle Scholar
  • 74 Joannides R, Bakkali E H, Leroy F. Altered flow-dependent vasodilatation of conduit arteries in maintenance haemodialysis.  Nephrol Dial Transplant . 1997;  12 2623-2628
    PubMedGoogle Scholar
  • 75 de Valk-de Roo G W, Stehouwer C DA, Lambert J. Plasma homocysteine is weakly correlated with plasma endothelin and von Willebrand factor, but not with endothelium-dependent vasodilatation in healthy postmenopausal women.  Clin Chem . 1999;  45 1200-1205
    PubMedGoogle Scholar
  • 76 Bellamy M F, Mcdowell I FW, Ramsey M W. Hyperhomocysteinemia after an oral methionine load acutely impairs endothelial function in healthy adults.  Circulation . 1998;  98 1848-1852
    PubMedGoogle Scholar
  • 77 Chambers J C, McGregor A, Jean-Marie J, Obeid O A, Kooner, J S. Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia-an effect reversible with vitamin C therapy.  Circulation . 1999;  99 1156-1160
    PubMedGoogle Scholar
  • 78 Usui M, Matsuoka H, Miyazaki H. Endothelial dysfunction by acute hyperhomocyst(e)inaemia: Restoration by folic acid.  Clin Sci . 1999;  96 235-239
    PubMedGoogle Scholar
  • 79 Kanani P M, Sinkey C A, Browning R L. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans.  Circulation . 1999;  100 1161-1168
    PubMedGoogle Scholar
  • 80 Verhaar M C, Wever R M, Kastelein J J. 5-Methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia.  Circulation . 1998;  97 237-241
    PubMedGoogle Scholar
  • 81 Mansoor M A, Kristensen O, Hervig T. Low concentrations of folate in serum and erythrocytes of smokers-methionine loading decreases folate concentrations in serum of smokers and nonsmokers.  Clin Chem . 1997;  43 2192-2194
    PubMedGoogle Scholar
  • 82 Nappo F, De Rosa N, Marfella R. Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins.  JAMA . 1999;  281 2113-2118
    CrossrefPubMedGoogle Scholar
  • 83 McAuley D F, Hanratty C G, McGurk C, Nugent A G, Johnston G D. Effect of methionine supplementation on endothelial function, plasma homocysteine, and lipid peroxidation.  J Toxicol Clin Toxicol . 1999;  37 435-440
    CrossrefPubMedGoogle Scholar
  • 84 Lentz S R, Malinow M R, Piegors D J. Consequences of hyperhomocyst(e)inemia on vascular function in atherosclerotic monkeys.  Arterioscler Thromb Vasc Biol . 1997;  17 2930-2934
    PubMedGoogle Scholar
  • 85 van Guldener C, Janssen M JFM, Lambert J. No change in impaired endothelial function after long-term folic acid therapy of hyperhomocysteinaemia in haemodialysis patients.  Nephrol Dial Transplant . 1998;  13 106-112
    PubMedGoogle Scholar
  • 86 van Guldener C, Janssen M JFM, Lambert J. Folic acid treatment of hyperhomocysteinemia in peritoneal dialysis patients: No change in endothelial function after long-term therapy.  Perit Dial Int . 1998;  18 282-289
    PubMedGoogle Scholar
  • 87 Ambrosi P, Rolland P H, Bodard H. Effects of folate supplementation in hyperhomocysteinemic pigs.  J Am Coll Cardiol . 1999;  34 274-279
    CrossrefPubMedGoogle Scholar
  • 88 Bellamy M F, McDowell I FW, Ramsey M W. Oral folate enhances endothelial function in hyperhomocysteinaemic subjects.  Eur J Clin Invest . 1999;  29 659-662
    CrossrefPubMedGoogle Scholar
  • 89 Mudd S H, Skovby F, Levy H L. The natural history of homocystinuria due to cystathionine beta-synthase deficiency.  Am J Hum Genet . 1985;  37 1-31
    PubMedGoogle Scholar
  • 90 van Beynum I M, Smeitink J AM, den Heijer M, te Poele Pothoff M TWB, Blom H J. Hyperhomocysteinemia-a risk factor for ischemic stroke in children.  Circulation . 1999;  99 2070-2072
    PubMedGoogle Scholar
  • 91 Stehouwer C DA, Weijenberg M P, van den Berg M. Serum homocysteine and risk of coronary heart disease and cerebrovascular disease in elderly men-A 10-year follow-up.  Arterioscler Thromb Vasc Biol . 1998;  18 1895-1901
    PubMedGoogle Scholar
      >